Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ildong Pharmaceutical Co. Ltd.

www.ildong.com/eng/

Latest From Ildong Pharmaceutical Co. Ltd.

Asia Deal Watch: Daiichi Sankyo Pays $200m To Ultragenyx For AAV Technology Access

A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context

Deals Business Strategies

How Can Korea Grab Window Of Opportunity In AI Drug Development?

Participants at a recent policy forum in Seoul stressed the need to secure appropriate technology and expertise, unify government support and draw up a joint cooperation plan between industry and government as key factors in advancing AI-guided new drug development in South Korea.

South Korea Artificial Intelligence

Cellivery IPO To Fund Potential First-In-Class Parkinson's Asset, May Speed Licensing Deal

Marking the first Korean company to launch an initial public offering on the recommendation of its lead broker, Cellivery Therapeutics is slated to use the upcoming proceeds to progress preclinical trials of its lead assets for Parkinson's disease and pancreatic cancer, which the company aims to license out to global partners in the early development stages.

South Korea Financing

Lilly Pays Nearly $1bn To Regain Migraine Candidate It Once Sold For $1m

In acquiring biotech CoLucid and its Phase III acute migraine candidate lasmiditan for $960m, Lilly gets back an asset it discovered and out-licensed more than a decade ago. The pharma hopes to pair the 5-HT1F agonist with galcanezumab to create a two-drug migraine franchise.

Deals M & A
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Ildong Pharmaceutical Co. Ltd.
  • Senior Management
  • Jung-chi Lee, PhD, CEO
  • Contact Info
  • Ildong Pharmaceutical Co. Ltd.
    Phone: 2 526 3534
    2 Baumoe-ro 27-gil
    Seocho-gu
    Seoul, 137733
    South Korea
UsernamePublicRestriction

Register